Orbimed Advisors LLC Sells 34,000 Shares of Danaher Corporation $DHR

Posted by George Bondi on Jul 27th, 2026

Orbimed Advisors LLC reduced its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 11.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 265,800 shares of the conglomerate’s stock after selling 34,000 shares during the quarter. Orbimed Advisors LLC’s holdings in Danaher were worth $50,396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. State Street Corp raised its position in Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock worth $6,345,529,000 after buying an additional 472,608 shares during the last quarter. Capital International Investors boosted its holdings in shares of Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after acquiring an additional 1,487,768 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Danaher by 9.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after acquiring an additional 1,334,221 shares during the period. Wellington Management Group LLP raised its holdings in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after purchasing an additional 1,517,904 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Danaher during the fourth quarter valued at approximately $2,177,106,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DHR. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday. DZ Bank initiated coverage on Danaher in a report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price target on the stock. Evercore restated an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Morgan Stanley cut their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a report on Wednesday, April 22nd. Finally, Robert W. Baird reduced their price objective on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

View Our Latest Research Report on Danaher

Danaher Trading Up 0.2%

Danaher stock opened at $191.87 on Monday. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The firm has a market capitalization of $134.88 billion, a price-to-earnings ratio of 34.08, a P/E/G ratio of 2.38 and a beta of 0.79. The firm has a 50 day moving average of $185.64 and a 200 day moving average of $196.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. As a group, research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.8%. Danaher’s dividend payout ratio is currently 28.42%.

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.